| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Silver bis(trifluoromethanesulfonyl)imide does not have a specific biological target. Its applications in drug discovery are primarily as a chemical reagent rather than a pharmacologically active compound. It has been reported to be used as an anticancer agent, but specific mechanisms of action are not well characterized in the literature. As a silver-containing compound, it may exert antimicrobial or anticancer effects through the release of silver ions, which can interact with cellular thiol groups and disrupt mitochondrial function. However, its primary use remains as a synthetic reagent.
|
|---|---|
| ln Vitro |
In vitro studies on silver bis(trifluoromethanesulfonyl)imide are limited as it is primarily a chemical reagent. It has been used to create methyl ketones by reacting with an alkyne in the presence of sodium carbonate and carbonyl compounds such as acetone or methyl ethyl ketone. Its potential anticancer activity has been mentioned, but detailed in vitro efficacy data against specific cancer cell lines are not readily available. The compound is more commonly used in organic synthesis and electrochemistry than in biological assays.
|
| ln Vivo |
In vivo data for silver bis(trifluoromethanesulfonyl)imide are limited as it is a chemical reagent rather than a drug candidate. While it has been mentioned as an anticancer agent, detailed animal studies are not available in the public domain. The compound's silver content may raise toxicity concerns for in vivo applications, as silver ions can accumulate in tissues and cause argyria. Its primary applications remain in materials science and organic synthesis.
|
| Enzyme Assay |
Silver bis(trifluoromethanesulfonyl)imide is not typically used in enzyme/receptor binding assays. Its role in drug discovery is as a sulfonylation reagent for organic synthesis. For compounds synthesized using this reagent, typical binding assays may be performed. These involve incubating the test compound with purified enzymes or receptors in buffered solutions at 25–37°C, with binding affinity measured by SPR, ITC, or fluorescence-based methods. The silver reagent itself is not directly assayed for biological binding.
|
| Cell Assay |
Cell-based assays are not typically performed with silver bis(trifluoromethanesulfonyl)imide. Its primary applications are in organic synthesis and electrochemistry. When used to synthesize drug candidates, the resulting compounds may be evaluated in cellular systems. Typical cell-based studies involve culturing cancer cell lines in appropriate media, treating with varying concentrations of the synthesized compound, and assessing cell viability, apoptosis, and other endpoints over 24–72 hours.
|
| Animal Protocol |
In vivo animal studies are not conducted with silver bis(trifluoromethanesulfonyl)imide as it is a chemical reagent. Drug candidates synthesized using this reagent may be evaluated in animal models for efficacy, pharmacokinetics, and toxicity. Typical studies involve oral or intravenous administration to rodents, with monitoring of plasma drug levels, tissue distribution, and disease-relevant endpoints. All studies are conducted in accordance with institutional animal care guidelines.
|
| ADME/Pharmacokinetics |
Silver bis(trifluoromethanesulfonyl)imide is a chemical reagent and is not subject to pharmacokinetic evaluation as a drug. Its physicochemical properties include a molecular weight of 388.014 g/mol. It should be stored away from direct sunlight, with powder stable at -20°C for up to 3 years and in solvent at -80°C for up to 1 year. The compound is sensitive to light and moisture. It is soluble in organic solvents and is used as an electrolyte in battery applications.
|
| Toxicity/Toxicokinetics |
The toxicological profile of silver bis(trifluoromethanesulfonyl)imide has not been extensively characterized. As a silver-containing compound, it may pose toxicity risks due to the potential release of silver ions, which can cause argyria (irreversible blue-gray discoloration of skin and mucous membranes) upon chronic exposure. Standard laboratory safety precautions should be observed, including the use of personal protective equipment (gloves, goggles, lab coat) and adequate ventilation. Ingestion, inhalation, and skin contact should be avoided.
|
| Additional Infomation |
Silver bis(trifluoromethanesulfonyl)imide is not a drug but a versatile chemical reagent used in organic synthesis, drug discovery, and materials science. In organic synthesis, it serves as a sulfonylation reagent and is used in the synthesis of prenylated compounds and methyl ketones. In electrochemistry, it is used as an electrolyte in lithium-ion batteries. It has also been mentioned as an anticancer agent, though this application is not well documented. It is not approved for clinical use.
|
| Molecular Formula |
C2AGF6NO4S2
|
|---|---|
| Molecular Weight |
388.01
|
| Exact Mass |
386.822
|
| CAS # |
189114-61-2
|
| PubChem CID |
15975413
|
| Appearance |
White to gray solid powder
|
| Melting Point |
249℃
|
| LogP |
3.22
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
16
|
| Complexity |
374
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(F)(F)(F)S(=O)(=O)[N-]S(=O)(=O)C(F)(F)F.[Ag+]
|
| InChi Key |
HSYLTRBDKXZSGS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C2F6NO4S2.Ag/c3-1(4,5)14(10,11)9-15(12,13)2(6,7)8;/q-1;+1
|
| Chemical Name |
silver;bis(trifluoromethylsulfonyl)azanide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (257.73 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5773 mL | 12.8863 mL | 25.7725 mL | |
| 5 mM | 0.5155 mL | 2.5773 mL | 5.1545 mL | |
| 10 mM | 0.2577 mL | 1.2886 mL | 2.5773 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
